Timothy E Albertson

Dr. Timothy E Albertson

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
SLSamuel Louie
Samuel Louie
AZAmir A Zeki
Amir A Zeki
MSMichael Schivo
Michael Schivo
ACAndrew L Chan
Andrew L Chan
KYKen Y Yoneda
Ken Y Yoneda
TATimothy E Albertson
Timothy E Albertson
Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the obstructive ...

24 February 2015 in JMIR Medical Informatics
Verified
Journal Article
Open access
ATAthanasios Tsoukalas
Athanasios Tsoukalas
TATimothy E Albertson
Timothy E Albertson
ITIlias Tagkopoulos
Ilias Tagkopoulos
Clinical informatics, decision support for health professionals, electronic health records, and ehealth infrastructures.

1 April 1999
Verified
Journal Article
Closed access
TATimothy E Albertson
Timothy E Albertson
RDR W Derlet
R W Derlet
BHB E Van Hoozen
B E Van Hoozen

1 March 2015
Verified
Journal Article
Open access
PDF file
MJMaya M. Juarez
Maya M. Juarez
ACAndrew L. Chan
Andrew L. Chan
ANAndrew G. Norris
Andrew G. Norris
BMBrian M. Morrissey
Brian M. Morrissey
TATimothy E Albertson
Timothy E Albertson
Acute exacerbation of idiopathic pulmonary fibrosis—a review of current and novel pharmacotherapies

19 January 2020 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
TATimothy E Albertson
Timothy E Albertson
JCJames A. Chenoweth
James A. Chenoweth
SPSkyler J. Pearson
Skyler J. Pearson
SMSusan Murin
Susan Murin
Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a disease phenotype that shares T helper lymphocyte cell Th1/neutrophilic/non-Type-2 Inflammation pathways thought to be key in COPD and Th2/eosinophilic/Type-2 inflammatory pathways of asthma. The pharmacology of treating ACOS is challenging in severe circumstances. Areas covered: This review evaluates the stepwise treatment of ACOS using pharmacological treatments used in both COPD and asthma. The most common medications involve the same inhalers used to treat COPD and asthma patients. Advanced stepwise therapies for ACOS patients are based on patient characteristics and biomarkers. Very few clinical trials exist that focus specifically on ACOS patients. Expert opinion: After inhalers, advanced therapies including phosphodiesterase inhibitors, macrolides, N-acetylcysteine and statin therapy for those ACOS patients with a COPD appearance and exacerbations are available. In atopic ACOS patients with exacerbations, advanced asthma therapies (leukotriene receptor antagonists and synthesis blocking agents.) are used. ACOS patients with elevated blood eosinophil/IgE levels are considered for immunotherapy or therapeutic monoclonal antibodies blocking specific Th2/Type-2 interleukins or IgE. Symptom control, stabilization/improvement in pulmonary function and reduced exacerbations are the metrics of success. More pharmacological trials of ACOS patients are needed to better understand which patients benefit from specific treatments. Abbreviations: 5-LOi: 5-lipoxygenase inhibitor; ACOS: asthma – COPD overlap syndrome; B2AR: Beta2 adrenergic receptors; cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine monophosphate; CI: confidence interval; COPD: chronic obstructive pulmonary disease; CRS : chronic rhinosinusitis; cys-LT: cysteinyl leukotrienes; DPI: dry powder inhaler; EMA: European Medicines Agency; FDA: US Food and Drug Administration; FDC: fixed-dose combination; FeNO: exhaled nitric oxide; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; GM-CSF: granulocyte-macrophage colony-stimulating factor; ICS : inhaled corticosteroids; IL: interleukin; ILC2: Type 2 innate lymphoid cells; IP3: Inositol triphosphate; IRR: incidence rate ratio; KOLD: Korean Obstructive Lung Disease; LABA: long-acting B2 adrenergic receptor agonist; LAMA: long-acting muscarinic receptor antagonist; LRA: leukotriene receptor antagonist; LT: leukotrienes; MDI: metered-dose inhalers; MN: M-subtype muscarinic receptors; MRA: muscarinic receptor antagonist; NAC: N-acetylcysteine; NEB: nebulization; OR: odds ratio; PDE: phosphodiesterase; PEFR: peak expiratory flow rate; PGD2: prostaglandin D2; PRN: as needed; RR: risk ratio; SABA: short-acting B2 adrenergic receptor agonist; SAMA: short-acting muscarinic receptor antagonist; SDMI: spring-driven mist inhaler; Th1: T helper cell 1 lymphocyte; Th2: T helper cell 2 lymphocytes; TNF-α: tumor necrosis factor alpha; US : United States

12 October 2011 in International Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
TATimothy E Albertson
Timothy E Albertson
KOKelly P Owen
Kelly P Owen
MSMark E Sutter
Mark E Sutter
ACAndrew L Chan
Andrew L Chan
To define the role of gastrointestinal (GI) decontamination of the poisoned patient. A computer-based PubMed/MEDLINE search of the literature on GI decontamination in the poisoned patient with cross referencing of sources. Clinical, animal and in vitro studies were reviewed for clinical relevance to GI decontamination of the poisoned patient. The literature suggests that previously, widely used, aggressive approaches including the use of ipecac syrup, gastric lavage, and cathartics are now rarely recommended. Whole bowel irrigation is still often recommended for slow-release drugs, metals, and patients who "pack" or "stuff" foreign bodies filled with drugs of abuse, but with little quality data to support it. Activated charcoal (AC), single or multiple doses, was also a previous mainstay of GI decontamination, but the utility of AC is now recognized to be limited and more time dependent than previously practiced. These recommendations have resulted in several treatment guidelines that are mostly based on retrospective analysis, animal studies or small case series, and rarely based on randomized clinical trials. The current literature supports limited use of GI decontamination of the poisoned patient.